Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2024)

Historic Change in Acquisitions & Divestments for Coherus Oncology (CHRS) over the last 7 years, with Q1 2024 value amounting to $8.7 million.

  • Coherus Oncology's Change in Acquisitions & Divestments fell 5035.43% to $8.7 million in Q1 2024 from the same period last year, while for Dec 2024 it was $8.7 million, marking a year-over-year decrease of 9398.17%. This contributed to the annual value of $8.7 million for FY2024, which is 9398.17% down from last year.
  • As of Q1 2024, Coherus Oncology's Change in Acquisitions & Divestments stood at $8.7 million, which was down 5035.43% from $36.2 million recorded in Q4 2023.
  • Coherus Oncology's 5-year Change in Acquisitions & Divestments high stood at $211.0 million for Q4 2020, and its period low was $8.7 million during Q1 2024.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $40.2 million (2021), whereas its average is $56.1 million.
  • In the last 5 years, Coherus Oncology's Change in Acquisitions & Divestments surged by 380740.74% in 2020 and then crashed by 8246.82% in 2021.
  • Quarter analysis of 4 years shows Coherus Oncology's Change in Acquisitions & Divestments stood at $211.0 million in 2020, then crashed by 82.47% to $37.0 million in 2021, then decreased by 2.11% to $36.2 million in 2023, then crashed by 76.01% to $8.7 million in 2024.
  • Its Change in Acquisitions & Divestments was $8.7 million in Q1 2024, compared to $36.2 million in Q4 2023 and $43.4 million in Q3 2023.